<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845101</url>
  </required_header>
  <id_info>
    <org_study_id>NNF17OC0027780</org_study_id>
    <nct_id>NCT03845101</nct_id>
  </id_info>
  <brief_title>CBT Versus CBT Augmented With Virtual Reality Exposure for Social Anxiety Disorder.</brief_title>
  <acronym>SO-REAL</acronym>
  <official_title>SO REAL- a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mental Health Services in the Capital Region, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mental Health Services in the Capital Region, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background Social Anxiety Disorder has high lifetime prevalence, early onset and long
      duration or chronicity. Exposure therapy is considered as one of the most effective element
      in cognitive behavioural therapy but in vivo exposure can be difficult to access and control,
      and is sometimes rejected by patients because they consider it too aversive. The use of
      virtual reality allows exposure to challenging situations in an immersive, but also
      protected, flexible and controlled environment.

      Aim The aim of the SO REAL-trial is to investigate the effect of cognitive behavioural
      therapy (CBT-In Vivo Exposure) versus cognitive behavioural therapy augmented with virtual
      reality exposure (CBT-Virtual Exposure) for patients diagnosed with social anxiety disorder.

      Methods The design is an investigator initiated randomized, assessor-blinded, parallel group
      and superiority designed clinical trial. From the psychotherapeutic outpatient clinics at
      Mental Health Centre Copenhagen, 302 patients, diagnosed with social anxiety disorder, will
      be included. All patients will be offered a manual-based 14 week cognitive behavioural
      treatment program, including 8 sessions with exposure therapy. Patients will be centrally
      randomised with concealed allocation sequence to cognitive behavioural therapy augmented with
      virtual reality exposure or cognitive behavioural therapy.

      Patients will be assessed at baseline, post treatment and at one-year follow-up by
      independent researchers blinded for treatment condition. The primary outcome will be social
      anxiety measured with Liebowitz Social Anxiety Scale. Secondary outcome measures will include
      depression, social functioning, and patient satisfaction. Exploratory outcomes will be
      substance and alcohol use, working alliance, quality of life.

      Perspectives The SO REAL trial will be the hitherto largest trial investigating the use of
      virtual reality as augmentation of cognitive behavioural therapy and the results may guide
      future clinical treatment
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2019</start_date>
  <completion_date type="Anticipated">April 9, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 9, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Liebowitz Social Anxiety Scale score</measure>
    <time_frame>Between 30 to 1 day(s) before treatment, up to two weeks after treatment and between 365 to 395 days after first assesment.</time_frame>
    <description>The total score on the Liebowitz Social Anxiety Scale (LSAS) measured pre treatment, post treatment and at one year follow up. LSAS assesses a range of situations typically feared by individuals with social anxiety. It has 24 items, divided into subscales of performance anxiety and social situations. It has acceptable psychometric properties. The score ranges from 0 to 144. Higher score is worse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton Depression Rating Scale, 6 item score</measure>
    <time_frame>Between 30 to 1 day(s) before treatment, between 0 and 14 days after treatment ends and between 365 to 395 days after first assesment.</time_frame>
    <description>Measures symptoms of depression for the last 3 days.Total score will be measured. Ranges from 0 to 22. Higher is worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Brief Version of the Fear of Negative Evaluation Scale score</measure>
    <time_frame>Between 30 to 1 day(s) before treatment, between 0 and 14 days after treatment ends and between 365 to 395 days after first assesment.</time_frame>
    <description>Self-report, total score is measured, ranging from 12 to 60. Higher is worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Work and Social Adjustment Scale score</measure>
    <time_frame>Between 30 to 1 day(s) before treatment, between 0 and 14 days after treatment ends and between 365 to 395 days after first assesment.</time_frame>
    <description>Self-report. Total score is measured, ranging from 0 to 40. Higher is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Client Satisfaction Questionnaire</measure>
    <time_frame>Measured between 0 and 14 days after treatment ends</time_frame>
    <description>Measures satisfaction with treatment. Total score is measured, ranging from 8 to 32. Higher is better. Self-report.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WHO Well-Being Index 5 items, score</measure>
    <time_frame>Between 30 to 1 day(s) before treatment, between 0 and 14 day(s) after treatment ends and between 365 to 395 days after first assesment.</time_frame>
    <description>Measures overall quality of life. Total score is measured. Ranges from 0 to 25. Higher is better. Self-report.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment</measure>
    <time_frame>Between 0 and 14 day(s) after treatment ends and between 365 to 395 days after first assesment.</time_frame>
    <description>(LSAS total score below 50 or a 15 points drop)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission from social anxiety disorder</measure>
    <time_frame>Between 0 and 14 day(s) after treatment ends and between 365 to 395 days after first assesment.</time_frame>
    <description>(LSAS total score below 25)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Personal and Social Performance Scale score</measure>
    <time_frame>Between 30 to 1 day(s) before treatment, between 0 and 14 day(s) after treatment ends and between 365 to 395 days after first assesment.</time_frame>
    <description>Measured as total score. Ranges from 0 to 100. Higher is better. Self-report.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Alchohol and drug (legal and illegal) use</measure>
    <time_frame>Between 30 to 1 day(s) before treatment, between 0 and 14 day(s) after treatment ends and between 365 to 395 days after first assesment.</time_frame>
    <description>Measured using the Time Line Follow Back interview, in which you systematically go through every day for the last 4 weeks recording any alcohol and drug (legal and illegal) consumption. Will be scored in units of 12 grams of alcohol and in grams of substance consumed. Less consumed alchohol and substance will be considered better.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in General Self Efficacy Scale Score</measure>
    <time_frame>Between 30 to 1 day(s) before treatment, between 0 and 14 day(s) after treatment ends and between 365 to 395 days after first assesment.</time_frame>
    <description>Measures general belief in ones own capabilities. Self-report. Total score is measured. Ranges from 10 to 40. Higher is better.</description>
  </other_outcome>
  <other_outcome>
    <measure>Working Alliance Inventory</measure>
    <time_frame>Measured between 0 and 14 days after treatment ends.</time_frame>
    <description>Measured the experience of alliance between the client and the therapist(s). Self-report. Total score is measured. Ranges from 12 to 60. Higher score is better.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">302</enrollment>
  <condition>Social Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>CBT In VR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives CBT in group format augmented with Virtual Reality Exposure Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBT in vivo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator, receives CBT in group format, TAU</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CBT augmented with VR</intervention_name>
    <description>The patients receiving the in VR exposure will be immersed using an Oculus Go head-mounted display enabling viewing of 360Â° live recorded VR environments. Five exposure scenarios have been developed based on general themes of the LSAS, patient feedback and clinical experience from a therapist panel. The five scenarios are as follows: 1) standing in line in a supermarket; 2) attending a party; 3) attending a formal meeting and giving a presentation; 4) small talking/debating in a canteen; and 5) entering an auditorium. Each scenario has four to six scenes of increasing difficulty as well as a neutral scene developed to familiarize patients with the VR setting and deescalating the anxiety response. The order of the scenarios viewed in these five sessions will be chosen by therapists based on the needs of the group. The last two VR exposure sessions are devoted to individual work with one or two previously explored virtual environments closest to the patient's difficulties.</description>
    <arm_group_label>CBT In VR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CBT in vivo</intervention_name>
    <description>The therapeutic intervention is manual-based cognitive behavioral group therapy (CBT) adapted from the approach of Turk, C., L., Heimberg, R.G. &amp; Magee, L. (2008). The treatment will consist of a total of 14 weekly two-hour group sessions performed in accordance with the manual to ensure a uniform and equal treatment for every patient throughout the study. Every session will be led by two trained clinical psychologists with practical experience in CBT and in vivo exposure.</description>
    <arm_group_label>CBT in vivo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfilling diagnostic criteria for social anxiety disorder (ICD-code: F40.1)

          -  Severity of social anxiety from moderate to severe degree (from cut-off 65 and up on
             the Liebowitz anxiety scale).

          -  Age 18-75 years

          -  Either not treated with antidepressants or unchanged doses of antidepressants for at
             least 4 weeks before inclusion and no change in antidepressants is anticipated,

          -  Sufficient knowledge of the Danish language

          -  Informed consent

        Exclusion Criteria:

          -  Alcohol or drug dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merete Nordentoft</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mental Health Centre Copenhagen (CORE)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin Arnfred</last_name>
    <phone>21630878</phone>
    <phone_ext>+45</phone_ext>
    <email>benjamin.alexander.thorup.arnfred@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Bang</last_name>
    <phone>21 62 93 40</phone>
    <phone_ext>+45</phone_ext>
    <email>peter.bang.01@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Psykoterapeutisk Klinik, Frederiksberg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <state>Capital Region Of Copenhagen</state>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Bang</last_name>
      <email>peter.bang.01@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Psykoterapeutisk Klinik, Nannasgade</name>
      <address>
        <city>Copenhagen</city>
        <state>Captial Region Of Denmark</state>
        <zip>2200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Arnfred</last_name>
      <phone>45 21 63 08 78</phone>
      <email>benjamin.alexander.thorup.arnfred@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>May 3, 2019</last_update_submitted>
  <last_update_submitted_qc>May 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Social anxiety</keyword>
  <keyword>Virtual Reality</keyword>
  <keyword>Virtual Reality Exposure Therapy</keyword>
  <keyword>RCT</keyword>
  <keyword>Social Phobia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Phobia, Social</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

